Moderna: CHMP gives green light to new Covid vaccine
This vaccine is intended for people aged six months and over for the autumn/winter 2024-2025 season. This decision is based on preclinical and clinical data demonstrating the vaccine's efficacy and safety.
Moderna has already obtained similar approvals in Japan, Taiwan and the UK, and continues to submit applications elsewhere. In the EU, the company is participating in a tender for Covid vaccines.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction